NAUT
insider transactionsNautilus Biotechnology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-5.0M
25.0K buy · 5.0M sell
Net value · 365d
-$11.7M
$65.2K in · $11.8M out
Sentiment · 365d
Net selling
1% buying · 99% selling
Open-market trades · 365d
3
25.0K buy · 5.0M sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
$902.5K
384.0K sh · $2.35
Own -28%
-
Sell·S
-
Buy·P
Sujal M Patel KEY
CEO, President, and Secretary
$65.2K
25.0K sh · $2.61
Own +0%
-
Grant·A
Chief Marketing Officer
$0
160.0K sh
Own New
-
Grant·A
Senior VP, Product Development
$0
160.0K sh
Own New
-
Grant·A
Chief People Officer
$0
160.0K sh
Own New
-
Grant·A
Sujal M Patel KEY
CEO, President, and Secretary
$0
650.0K sh
Own New
-
Grant·A
General Counsel
$0
160.0K sh
Own New
-
Grant·A
Anna Mowry KEY
CFO and Treasurer
$0
160.0K sh
Own New
-
Grant·A
Chief Scientist
$0
280.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. / Andreessen Horowitz LSV Fund II, L.P. / AH Bio Fund II, L.P. / AH Equity Partners LSV II, L.L.C. / Marc L Andreessen / Benjamin A Horowitz | Sell S | 384.0K | $902.5K |
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. / Andreessen Horowitz LSV Fund II, L.P. / AH Bio Fund II, L.P. / AH Equity Partners LSV II, L.L.C. / Marc L Andreessen / Benjamin A Horowitz | Sell S | 4.6M | $10.8M |
| Mar 4, 2026 | Sujal M Patel KEY | Buy P | 25.0K | $65.2K |
| Mar 2, 2026 | Kentaro Suzuki | Grant A | 160.0K | $0 |
| Mar 2, 2026 | Subramanian Sankar | Grant A | 160.0K | $0 |
| Mar 2, 2026 | Gwen E Weld | Grant A | 160.0K | $0 |
| Mar 2, 2026 | Sujal M Patel KEY | Grant A | 650.0K | $0 |
| Mar 2, 2026 | Matthew B. Murphy | Grant A | 160.0K | $0 |
| Mar 2, 2026 | Anna Mowry KEY | Grant A | 160.0K | $0 |
| Mar 2, 2026 | Parag Mallick | Grant A | 280.0K | $0 |
About NAUT insider trading
This page tracks insider transactions for Nautilus Biotechnology, Inc. (NAUT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.